Alnylam Stock Soars on Strong Results in Heart Drug Study
- Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare heart condition.
- 06/24/2024
|
Alnylam Pharmaceuticals reports promising heart disease trial results
- Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.
- 06/24/2024
|
Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds
- Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascular events in a study of patients with a rare heart disease.
- 06/24/2024
|
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
- Heart disease drugmaker Alnylam (NASDAQ: ALNY ) stock rose sharply on the success of a Phase 3 study of its heart drug, vutrisiran. The drug is also sold as Amvuttra.
- 06/24/2024
|
Cramer's Stop Trading: Alnylam Pharma
- CNBC's Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma.
- 06/24/2024
|
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
- Monday, Alnylam Pharmaceuticals Inc ALNY revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
- 06/24/2024
|
Alnylam Stock Soars After Positive Results From Heart Disease Study
- The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
- 06/24/2024
|
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
- Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
- 06/24/2024
|
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
- Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 06/24/2024
|
Alnylam's heart disease drug meets main goal in late-stage study
- Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease.
- 06/24/2024
|
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events du.
- 06/24/2024
|
The 'Undercovered' Dozen From June 1-6
- The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.
- 06/07/2024
|
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
- Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
- 06/05/2024
|
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
- Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100. The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.
- 06/03/2024
|
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
- Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
- 05/03/2024
|
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants David Lebowitz – Citi Paul Matteis – Stifel Maury Raycroft – Jefferies Gary Nachman – Raymond James Tazeen Ahmad – BofA Securities Ritu Baral – TD Cowen Jessica Fye – JPMorgan Kostas Biliouris – BMO Capital Markets Ellie Merle – UBS Gena Wang – Barclays Mike Ulz – Morgan Stanley Whitney Ijem – CG Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Quarter One 2024 Conference Call.
- 05/02/2024
|
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/02/2024
|
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
- Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago.
- 05/02/2024
|
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights. “2024 is off to a strong start, with exceptional commercial performance where we delivered $365 million in global net product revenues, representing 32% year-over-year growth for our four wholly owned products. We also made great progress with o.
- 05/02/2024
|
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
- 04/30/2024
|
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
- The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam's innovative RNAi technologies ZUG, Switzerland, April 30, 2024 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets. Medison, the creator and leader of the multi-regional partnership category, has established a unique, unified commercialization platform in international markets, particularly for the treatment of rare and severe diseases.
- 04/30/2024
|
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/25/2024
|
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future via conference call on Thursday, May 2, 2024 at 8:30 am ET. To access the call, please r.
- 04/18/2024
|
ALNY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
- NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 04/18/2024
|
Levi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNY
- NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 04/17/2024
|
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
- NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 04/11/2024
|
ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 04/10/2024
|
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
- NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 04/09/2024
|
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
- Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/08/2024
|
Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY
- NEW YORK, NY / ACCESSWIRE / April 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 04/08/2024
|
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). Zilebesiran is an investigational RNAi t.
- 04/07/2024
|
Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud
- NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 03/29/2024
|
Investors who lost money on Alnylam Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALNY
- NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 03/28/2024
|
Alnylam Being Investigated on Behalf of Alnylam Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
- NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.
- 03/26/2024
|
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology (ACC) Scientific Session on Sunday, April 7, 2024 at 7:00 pm ET. The event will include pr.
- 03/20/2024
|
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
- Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.
- 03/06/2024
|
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
- Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.
- 02/16/2024
|
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript
- 02/15/2024
|
Why Alnylam Pharmaceuticals Stock Is Sinking Today
- Alnylam reported mixed fourth-quarter results. The company also announced changes to its Helios-B phase 3 study of vutrisiran in ATTR-CM.
- 02/15/2024
|
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/15/2024
|
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/08/2024
|
Alnylam's Huge Opportunity
- Pfizer's drug tafamidis has shown positive results in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), but there is still room for improvement. Alnylam's gene silencer treatments, ONPATTRO and vutrisiran, have shown promise in reducing levels of the transthyretin protein in the body. Alnylam's Phase 3 trial for vutrisiran in ATTR-CM, HELIOS-B, is expected to release results in early 2024 and could be a game changer in the market.
- 01/12/2024
|
Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues
- Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.
- 01/08/2024
|
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2023 global net product revenues. A live au.
- 01/02/2024
|
5 Biotech Acquisition Targets To Accumulate In 2024
- Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.
- 12/21/2023
|
3 biotech powerhouses poised to thrive amid sector rebound
- The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally and turnaround off its 52-week lows.
- 12/08/2023
|
Alnylam to Webcast Virtual R&D Day
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company's website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA inter.
- 12/06/2023
|
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
- Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.
- 11/03/2023
|
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/19/2023
|
Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran
- We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company's next-generation inverse RNA or RNAi candidate, in treating cardiac amyloidosis in the upcoming Phase 3. My price target for Alnylam Pharmaceuticals, Inc. common stock is $300, representing a 76% upside based on the discounted cash flow valuation method.
- 10/13/2023
|
Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One
- Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack of meaningful evidence of clinical efficacy. Amvuttra has always been the bigger opportunity in ATTR-CM, and now investors await the pivotal HELIOS-B clinical data in early 2024. Despite a good track record of drug development, ATTR-CM has been a tough target for Alnylam, and past failures (revusiran and Onpattro) are likely to drive elevated skepticism for HELIOS-B.
- 10/10/2023
|
Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
- Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.
- 10/10/2023
|
Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma
- Tesla (TSLA) shares are in focus as China-made EV demand drops by 10%, affecting Model 3 and Y sales. Tesla's delivery and production data declined from last quarter following a report by the China Passenger Car Association.
- 10/09/2023
|
Alnylam Stock Is Dropping on Surprising FDA Rejection
- Drugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside advisory committee voted in favor of it.
- 10/09/2023
|
US FDA declines approval for expanded use of Alnylam's heart-disease drug
- The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals' drug to treat a rare and fatal heart disease, citing insufficient evidence of clinical meaningfulness, the company said on Monday.
- 10/09/2023
|
Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter
- Alnylam Pharmaceuticals Inc. ALNY, -1.00% said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as a treatment for the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis after receiving a complete response letter from the U.S. Food and Drug Administration. Patisiran is already approved for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
- 10/09/2023
|
2 Growth Stocks That Could Rocket Higher Before the End of 2023
- Upcoming announcements from the U.S. Food and Drug Administration could cause several biotech stocks to rocket higher. Alnylam is expecting a decision regarding a progressive heart condition that could lead to billions in additional annual sales.
- 10/08/2023
|
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new results for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2023, October 6-9, 2023. Data from an interim analysis of the ongoing open-label extension.
- 10/06/2023
|
Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod
- Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.
- 09/14/2023
|
Alnylam Pharmaceuticals shares fall after FDA advisers weigh in on heart-disease drug
- Alnylam Pharmaceuticals Inc. ALNY, +3.89% shares fell more than 8% premarket on Thursday after advisers to the U.S. Food and Drug Administration on Wednesday weighed the risks and benefits of the company's treatment for a serious heart condition known as ATTR-CM. The FDA advisory committee voted 9 to 3 that the benefits of the treatment, Onpattro, outweigh its risks in patients with ATTR-CM, but the committee's comments suggest that the drug's label may be limited, analysts say.
- 09/14/2023
|
U.S. FDA panel backs expanded use of Alnylam's gene silencing drug
- An outside panel of experts to the U.S. Food and Drug Administration on Wednesday backed the expanded use of Alnylam Pharmaceuticals' gene silencing drug to treat a type of heart disease associated with a rare organ-damaging disorder.
- 09/13/2023
|
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
- The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the quality of life of millions of people.
- 09/13/2023
|
Alnylam Pharmaceuticals' stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR Amyloidosis
- Alnylam Pharmaceuticals Inc. ALNY, +3.89% said Wednesday its stock will be halted on Nasdaq through the day as a regulatory advisory committee will meet to review its new drug application for a treatment for the Cardiomyopathy of ATTR Amyloidosis. The treatment called onpattro, or patisiran, is approved in the U.S. and Canada for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults.
- 09/13/2023
|
Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility
- Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committee vote. Onpattro has met or exceeded the efficacy targets established with the FDA, but I expect the AdComm panelists to challenge the validity of those targets. Alnylam released positive top-line data from the KARDIA-1 Phase II study of zilebesiran, and this looks like a contender in the large hypertension market.
- 09/09/2023
|
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
- Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.
- 09/08/2023
|
3 Stocks to Buy For the COVID Resurgence
- The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.
- 09/07/2023
|
Alnylam hypertension drug meets main goal in mid-stage study
- Alnylam Pharmaceuticals said on Thursday its experimental therapy for hypertension met the main goal in a mid-stage study.
- 09/07/2023
|
Alnylam to appeal ruling on patents related to Moderna's COVID vaccines
- Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spikevax.
- 08/25/2023
|
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
- Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
- 08/04/2023
|
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2023 Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer and EVP, Development & Medical Affairs Jeff Poulton - Chief Financial Officer Conference Call Participants Michael Ulz - Morgan Stanley David Lebowitz - Citi Paul Matteis - Stifel Ritu Baral - TD Cowen Maury Raycroft - Jefferies Eliana Merle - UBS William Pickering - Bernstein Gena Wang - Barclays Leland Gershell - Oppenheimer Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q2 2023 Earnings Conference Call.
- 08/03/2023
|
Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/03/2023
|
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnyl.
- 08/02/2023
|
Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline
- Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a very long development timeline for the candidate. The deal does look like a win-win and sweetens the bad news on the timeline side and it should significantly reduce the cost of development for Alnylam.
- 07/30/2023
|
Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche
- Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.
- 07/24/2023
|
Roche enters partnership with Alnylam for hypertension therapy
- Swiss pharmaceutical group Roche said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hypertension in patients with high cardiovascular risk.
- 07/24/2023
|
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
- Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/20/2023
|
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
- Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
- 07/20/2023
|
Why Alnylam Pharmaceuticals Topped the Market Today
- The biotech is a foot soldier in the war against Alzheimer's disease. It published encouraging interim results from a phase 1 study of its Alzheimer's treatment.
- 07/17/2023
|
Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date
- Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.
- 07/03/2023
|
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an investigational treatment for the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis. As previously announced, the FDA has set an.
- 06/30/2023
|
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT (11:00 am ET) at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.co.
- 06/05/2023
|
Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines
- Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its patents.
- 05/26/2023
|
Alnylam (ALNY) Reports Positive Results From APOLLO-B Study
- Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.
- 05/22/2023
|
3 Pharma Stocks That Could See a Surge in Demand in 2023
- As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector's positive momentum.
- 04/24/2023
|
These Are the Top 10 Holdings of Avoro Capital Advisors
- Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
- 04/17/2023
|
3 Growth Stocks That Could Disrupt the Healthcare Industry
- Healthcare growth stocks are often sought out by investors looking for market disruptors. That's because these stocks can potentially deliver high revenue growth, earnings, and stock price.
- 03/13/2023
|
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
- Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.
- 02/24/2023
|
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2022 Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer Jeff Poulton - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen David Lebowitz - Citi Tazeen Ahmad - Bank of America Securities Maury Raycroft - Jefferies Paul Matteis - Stifel Gena Wang - Barclays Luca Issi - RBC Myles Minter - William Blair Eliana Merle - UBS Operator Thank you for standing by and welcome to the Alnylam Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. As a reminder today's conference call is being recorded.
- 02/23/2023
|
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
- Alnylam (ALNY) delivered earnings and revenue surprises of 21.13% and 9.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2023
|
Should You Buy Alnylam Pharmaceuticals (ALNY) Ahead of Earnings?
- Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/22/2023
|
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
- CAMBRIDGE, Mass.--( BUSINESS WIRE )--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open.
- 02/02/2023
|
5 Best and Worst Performing Health Care Stocks in December 2022
- Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.
- 01/23/2023
|
Alnylam Pharmaceuticals Starts 2023 With In-Line Revenue And A Full Slate Of Clinical Read-Outs
- Alnylam's fourth quarter product revenue was more or less as expected, with a faster/better-than-expected pace of switching between Onpattro and Amvuttra and further patient growth in Oxlumo and Givlaari. Investors will have multiple clinical read-outs to anticipate this year, including Phase I results from ALN-APP (Alzheimer's) and Phase II results from the zilebesiran hypertension program.
- 01/10/2023
|
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
- Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
- 01/09/2023
|
VERA Dips Despite Positive Data From IgA Nephropathy Study
- VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
- 01/04/2023
|
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass.--( BUSINESS WIRE )--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2022 global net product revenues.
- 01/03/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy
- Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.
- 12/09/2022
|
Deal Activity Could Jumpstart Biotechnology
- Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of many large biopharma companies, providing ample dry powder for M&A.
- 10/31/2022
|
Alnylam Pharmaceuticals Offers Proven, Undervalued RNAi Platform, But Doubts Around ATTR Program Remain
- Alnylam's third quarter results were basically on target, with a stronger Amvuttra launch leading to more Onpattro switchovers, and some weakness in Givlaari and Oxlumo. There are still multiple credible and significant questions about whether Onpattro data will support widespread use in ATTR-CM and whether Amvuttra will be substantially better.
- 10/31/2022
|
Alnylam: Good Start For Amvuttra, Unanswered Regulatory Questions On Onpattro
- Alnylam missed Q3 revenue and EPS estimates, primarily due to lower-than-expected collaboration revenue. Amvuttra is off to a strong start in the United States with new patient starts doubling the previous pace of Onpattro in the first four months on the market.
- 10/31/2022
|
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2022 Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Akshay Vaishnaw - President Jeff Poulton - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Eliana Merle - UBS Ritu Baral - Cowen Jessica Fye - JPMorgan David Lebowitz - Citi Gena Wang - Barclays Paul Matteis - Stifel Gary Nachman - BMO Luca Issi - RBC Capital Joseph Stringer - Needham & Company Myles Minter - William Blair Operator Thank you for standing by and welcome to the Alnylam Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, today's conference call is being recorded.
- 10/27/2022
|
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3
- Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.
- 10/27/2022
|
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- 10/20/2022
|
Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock?
- Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 10/14/2022
|
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion
- The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
- 10/07/2022
|
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
- The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
- 09/21/2022
|
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer presentations from Alnylam scientists and program leaders who will review recent progress in a selection of the Company's pipeline programs and platform innovations, as well as medical thought leaders who will provide their perspectives on clin
- 09/19/2022
|
These Are The Five Best And Worst Performing Large-Cap Stocks In August 2022
- Large companies are set to face a new set of challenges in the coming months stemming from Russia's invasion of Ukraine, rising interest rates, and the COVID-19 pandemic.
- 09/13/2022
|
Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?
- Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 09/09/2022
|
Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market
- They're both soaring thanks to a handful of recent catalysts.
- 09/04/2022
|
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
- Biotech stocks are scorching right now. But the best of the best have strong gains.
- 08/29/2022
|
Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why
- Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.
- 08/26/2022
|
Can Intellia One-Up Alnylam In Transthyretin Amyloidosis?
- Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR.
- 08/23/2022
|
Is Alnylam Stock Poised For More Gains After A Stellar 50% Rise In A Month?
- Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 51% in a month.
- 08/23/2022
|
3 Biopharmas on Buyout Watch
- These three biotech companies could be headed for a buyout soon.
- 08/22/2022
|
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, during a late-breaker session at the 18th International Symposium on Amyloidosis (ISA) on September 8, 2022. The Company announced positive topline
- 08/18/2022
|
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
- A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned appeared first on Investor's Business Daily.
- 08/04/2022
|
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
- Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the entire industry.
- 08/03/2022
|
Why Is Alnylam (ALNY) Stock Up 50% Today?
- Today, Alnylam Pharmaceuticals (NASDAQ: ALNY ) revealed positive top-line results for the company's transthyretin-mediated amyloidosis treatment, patisiran. Alnylam's drug reportedly met its primary endpoint for selected trial participants, and consequently, ALNY stock is roaring higher today.
- 08/03/2022
|
Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today
- The RNAi drugmaker hits the mark in a rare form of heart failure.
- 08/03/2022
|
Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why
- Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study. The post Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why appeared first on Investor's Business Daily.
- 08/03/2022
|
Alnylam's stock jumps 57% after sharing positive news for its experimental RNAi therapy
- Shares of Alnylam Pharmaceuticals Inc. ALNY, +1.44% soared 57.0% in premarket trading on Wednesday after the company said its investigational RNAi therapeutic for a type of heart failure met the primary endpoint in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled study enrolled 360 adult patients in 21 countries.
- 08/03/2022
|
Alnylam's Strategy Is Getting Bigger. Time to Buy?
- After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.
- 07/30/2022
|
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q2 2022 Results - Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Akshay Vaishnaw – President Jeff Poulton – Chief Financial Officer Conference Call Participants Paul Matteis – Stifel David Lebowitz – Citi Salveen Richter – Goldman Sachs Ritu Baral – Cowen Tazeen Ahmad – Bank of America Joseph Stringer – Needham Maury Raycroft – Jefferies Luca Issi – RBC Capital Gary Nachman – BMO Anupam Rama – J.P. Morgan Gena Wang – Barclays Eliana Merle – UBS Myles Minter – William Blair Olivia Brayer – Cantor Operator Hello, thank you for standing by.
- 07/28/2022
|
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Misses Revenue Estimates
- Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2022
|
Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out
- Results from the APOLLO-B study are due any day now and will significantly impact sentiment around ALNY shares, as well as the revenue potential of Onpattro. A clearly successful outcome could quadruple revenue, but it's possible that the trial could meet its primary outcome and fail to show sufficient benefits in secondary outcomes (or vice versa).
- 07/18/2022
|
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
- The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
- 06/14/2022
|
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
- Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
- 06/10/2022
|
Time to Weed Your Holdings and Upgrade Your Portfolio
- With the stock market down 18% from its peak as of May 20, now is a good time for a portfolio upgrade.
- 05/23/2022
|
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
- Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
- 05/19/2022
|
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
- Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues.
- 04/29/2022
|
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q1 2022 Results - Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President of Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer Jeff Poulton - Chief Financial Officer Conference Call Participants David Lebowitz - Citigroup Maury Raycroft - Jefferies Salveen Richter - Goldman Sachs Paul Matteis - Stifel Matthew Harrison - Morgan Stanley Ritu Baral - Cowen Tazeen Ahmad - Bank of America Gena Wang - Barclays Anupam Rama - JPMorgan Operator Good day, and thank you for standing by. Welcome to the Alnylam Pharmaceuticals First Quarter 2022 Earnings Conference Call.
- 04/28/2022
|
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue Estimates
- Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2022
|
Alnylam's (ALNY) Vutrisiran NDA Faces Delay in FDA Decision
- The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the delay
- 04/05/2022
|
7 Biotech Stocks to Buy With Key Catalysts for April
- Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.
- 04/05/2022
|
See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis
- The FDA has extended the review timeline for Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) marketing application for vutrisiran for transthyretin-mediated (ATTR) amyloidosis. The updated Prescription Drug User Fee Act (PDUFA) goal date is July 14.
- 04/04/2022
|
Stellar Sales Growth Trend Makes Alnylam Pharmaceuticals Stock A Wise Bet
- We think that Alnylam Pharmaceuticals stock, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, currently is a better pick compared to Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, despite ALNY being the more.
- 03/31/2022
|
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- 03/29/2022
|
Alnylam: Suing Moderna, Pfizer Over LNP Technology. There May Be Method In This Madness
- Alnylam: Suing Moderna, Pfizer Over LNP Technology. There May Be Method In This Madness
- 03/23/2022
|
Alnylam files patent infringement lawsuits against Pfizer, Moderna
- Alnylam Pharmaceuticals Inc said on Thursday it has separately filed lawsuits against Pfizer Inc and Moderna Inc, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.
- 03/17/2022
|
Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
- Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
- 02/12/2022
|
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Revenues Beat
- Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.
- 02/11/2022
|
The Vanguard Health Care Fund's Top 5 Trades
- The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.
- 02/10/2022
|
Alnylam Pharmaceuticals' (ALNY) CEO Yvonne Greenstreet on Q4 2021 Results - Earnings Call Transcript
- Alnylam Pharmaceuticals' (ALNY) CEO Yvonne Greenstreet on Q4 2021 Results - Earnings Call Transcript
- 02/10/2022
|
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
- Alnylam Pharmaceuticals Inc's ALNY Q4 product revenues increased 76% Y/Y to $198.5 million, primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commercial product, Oxlumo. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/10/2022
|
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
- Alnylam (ALNY) delivered earnings and revenue surprises of -46.94% and 8.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/10/2022
|
12 biotech stocks to consider buying now as prospects for the sector brighten this year
- Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
- 02/06/2022
|
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/03/2022
|
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2021 on Thursday, February 10, 2022, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2021 results as well as expectations for the future via conference call on Thursday, February 10, 2022 at 8
- 01/24/2022
|
Alnylam: Biotech To Watch With Potential FDA Approval Of Vutrisiran For Rare Disease
- Alnylam reported positive 18-month results using its drug vutrisiran for the treatment of patients with ATTR with polyneuropathy. A PDUFA date is set for April 14, 2022, for the potential approval of vutrisiran for the treatment of patients with ATTR with polyneuropathy.
- 01/22/2022
|
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease
- Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis. Transthyretin amyloidosis is characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.
- 01/21/2022
|
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting. The meeting will be held January 21-22 in Pa
- 01/14/2022
|
Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies
- Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.
- 01/07/2022
|
Which Stocks To Buy Now? 4 Biotech Stocks To Know
- These biotech stocks could be worth watching in 2022.
- 01/07/2022
|
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Monday, January 10, 2022 at 9:45 am ET. This presentation will include an update on unaudited fourth quarter and full year 2021 global net product revenues. In addition, the Company will webcast the Q&A breakout session immediately
- 01/03/2022
|
4 Biotechs That Could Be Potential Takeover Targets in 2022
- We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
- 12/30/2021
|
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
- The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is indicated in the U.S. as an adjunct to diet and maximally tolerated statin therapy to treat clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia, requiring additional LDL-C lowering.
- 12/23/2021
|
M&A madness: Top analyst on how biotech could rebound in 2022
- Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.
- 12/15/2021
|
Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU
- Alnylam (ALNY) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.
- 12/15/2021
|
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
- Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.
- 12/14/2021
|
3 Under-the-Radar Biotech Stocks to Buy in 2022
- They may deliver major gains down the road.
- 12/11/2021
|
Alnylam Pharmaceuticals (ALNY) Stock: $205 Price Target From Needham
- The shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have received a price target of $205 from Needham. These are the details.
- 11/22/2021
|
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
- RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M&A optionality is "nice" to have, analyst Luca Issi's call is fundamental.
- 11/22/2021
|
What's Happening With Alnylam Stock?
- The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, plunged over 15% in yesterday's trading session, following its Q3 results, which were much lower than the Wall Street estimates. The company reported.
- 11/01/2021
|
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
- Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021.
- 10/29/2021
|
Why Alnylam Pharmaceuticals Stock Is Tanking This Week
- The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.
- 10/29/2021
|
Why Alnylam Pharmaceuticals Is Crashing Today
- The company's earnings fell short of expectations and its CEO is leaving.
- 10/28/2021
|
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2021 results as well as expectations for the future via conference call on Thursday, October 28, 2021 at 8:30 am ET. To access the
- 10/14/2021
|
Alnylam: Potential Is In Line With Current Valuation
- Alnylam is seeing sales ramp and could get more drugs approved in January and April 2022.
- 10/07/2021
|
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi therapeutics platform innovation and scientific leadership. The research was presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held virtually from September 26 – 29, 2021. Among the presentations from Alnylam scientists, new pre-clinical data were presented iden
- 09/29/2021
|
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:30 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after t
- 09/28/2021
|
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
- Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
- 09/14/2021
|
Alnylam (ALNY) Up 7.4% Since Last Earnings Report: Can It Continue?
- Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock?
- 09/02/2021
|
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 pm ET H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 7:00 am ET BofA Global Healthcare Conference on Thursday, September 16, 20
- 09/01/2021
|
Will Alnylam Stock Continue To Make New Highs?
- Going by historical performance, there is a slightly higher chance of more gains in ALNY stock over the next month.
- 08/30/2021
|
Alnylam Pharmaceuticals Flying High Despite Limited Near-Term Clinical Catalysts
- Alnylam reported second quarter results that included modest outperformance in product revenue, including 12% qoq growth in Onpattro. 2022 should be a big year for the ATTR-CM program, with APOLLO-B results and a possible early look at HELIOS-B.
- 08/10/2021
|
Alnylam's (ALNY) Q2 Earnings Miss Estimates, 2021 Guidance Up
- Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021.
- 08/04/2021
|
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q2 2021 Results - Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q2 2021 Results - Earnings Call Transcript
- 08/03/2021
|
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
- Alnylam (ALNY) delivered earnings and revenue surprises of -2.55% and 10.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2021
|
PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope
- Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and PeptiDream Inc have announced a license and collaboration agreement to discover and develop peptide-siRNA conjugates to deliver RNAi therapeutics to tissues outside the liver. Under the alliance, Alnylam will pick out a set of receptors, and PeptiDream will tailor-make a peptide for each.
- 07/30/2021
|
Alnylam's Lumasiran Substantially Reduces Plasma Oxalate Levels PH1 Patients With Severe Renal Impairment
- Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function. Lumasiran is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1), the gene encoding glycolate oxidase (GO).
- 07/29/2021
|
Analysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out for
- Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/27/2021
|
Here's What Drove Gene Editing Stocks Higher This Week
- The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
- 07/02/2021
|
What's Next For Alnylam Stock After The Recent Positive Development For Intellia?
- The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1% drop over the last five trading days, after another pharmaceutical company - Intellia Therapeutics - announced positive findings from.
- 07/01/2021
|
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance
- The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.
- 06/25/2021
|
What's Next For Alnylam Stock After The Recent 22% Rise?
- The stock price of Alnylam Pharmaceuticals, a relatively smaller pharmaceutical company with a market capitalization of $18 billion, has seen a 22% rise over the last twenty-one trading days, and we believe the stock will likely continue to rally in the near term. The 22% rise can primarily be.
- 06/11/2021
|
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1). These data were presented at the American Society of Pediatric Nephro
- 05/03/2021
|
Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat
- Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.
- 04/30/2021
|
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q1 2021 Results - Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q1 2021 Results - Earnings Call Transcript
- 04/29/2021
|
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced full positive results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, which met its primary and both secondary endpoints at nine months in patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy. The results were presented today in an
- 04/19/2021
|
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim results from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for the treatment of hypertension. Results were presented during a late-breaking oral presentation at the 2021 Joint Meeting of the European Society of Hypertension (ESH) and the International Societ
- 04/11/2021
|
Alnylam, Vir Biotech Deprioritize COVID-19 Drug Development In Hushed Manner
- Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GSK4182136). The therapy demonstrated an 85% reduction in hospitalization or death in the VIR-7831 arm than the placebo.
- 03/17/2021
|
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences which are being held virtually: Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 pm ET H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am ET Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 1:15 pm ET A live
- 02/22/2021
|
Delta Air, Foot Locker, Nvidia, Petrobras and More Monday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets could not make up their mind on a direction.
- 02/22/2021
|
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q4 2020 Results - Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q4 2020 Results - Earnings Call Transcript
- 02/11/2021
|
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
- Alnylam (ALNY) delivered earnings and revenue surprises of -8.29% and 14.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/11/2021
|
Recap: Alnylam Pharmaceuticals Q4 Earnings
- Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 19.19% over the past year to ($1.60), which beat the estimate of ($1.76).
- 02/11/2021
|
Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the Company's planned transition to a top-5 biotech (measured by market capitalization) in the next 5 years through: sustainable innovation yielding transformative medicines for rare and common diseases for patients around the world and delivery of exceptional financial performance. Alnylam P5x25 extends the Co
- 01/10/2021
|
Alnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis Program
- Alnylam announced that the HELIOS-A Phase III study of vutrisiran for hATTR-polyneuropathy achieved all of its primary and secondary endpoints. Vutrisiran's improved dosing profile and tolerability are important positives, but the real value-driver is the HELIOS-B study in ATTR-cardiomyopathy, a much larger market.
- 01/08/2021
|
Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study
- Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.
- 01/08/2021
|
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 am ET. This presentation will include an update on unaudited fourth quarter and full year 2020 global net product revenues. In addition, the Company will webcast the Q&A breakout session immediately following its presentat
- 01/04/2021
|
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial Officer where he will lead global marketing, sales, market access, commercial operations, training, new product commercialization and commercial strategy for the Company. Tolga will also join the Company's Management Board. In addition, Alnylam has recruited an experienced team of leaders across
- 12/21/2020
|
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, the Company plans to showcase its commercial and R&D progress, including its product and pipeline goals for 2021, focused on continued commercial execution and advancement of early-, mid- and late-stage investigational programs. Alnylam will also provide an update on its progress toward achieving a
- 12/15/2020
|
Alnylam to Webcast Virtual R&D Day
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company's website, www.alnylam.com, on December 15 and 16, 2020. In addition to presentations from Alnylam senior leaders, the event will include presentations from the following guest speakers: Akshay Desai, M.D., M.P.H. Director, Cardiomyopathy and Heart Failure Progra
- 12/08/2020
|
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company's Approved Therapies
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two new reports: the second annual update on its Patient Access Philosophy and its first-ever Rare Disease Trend Report. Together, the reports illuminate both the strategies by which the company has been able to maximize access for its approved medicines around the world, and the barriers associated with coverage for rare disease therapies. The Patient Access P
- 12/07/2020
|
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C Phase 3 study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of adults and children with advanced primary hyperoxaluria type 1 (PH1). Enrollment was completed with 21 PH1 patients across 13 sites in 10 countri
- 12/03/2020
|
Reasons Alnylam Is a Top Biotech Stock to Buy Right Now
- The company's rare disease treatments are a huge success and there will probably be a lot more of them.
- 11/30/2020
|
Alnylam's RNAi Therapies Make It A Buy
- Revenue is growing at a high percentage rate, but on a small base. Heavy investment in R&D will pay off as the decade progresses.
- 11/28/2020
|
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq Virtual Investor Conference on Friday, December 4, 2020 at 11:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event. Abou
- 11/25/2020
|
Alnylam Seeing A Rebound In Onpattro And Encouraging Early-Stage Hypertension Data
- Alnylam exceeded third-quarter sales expectations, with a stronger-than-expected recovery in Onpattro and healthy Givlaari sales. Another look at the Phase I ALN-AGT study showed double-digit blood pressure reductions with a clean safety profile and convenient dosing.
- 11/16/2020
|
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q3 2020 Results - Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Were These Hedge Funds Wrong About Alnylam Pharmaceuticals, Inc. (ALNY)?
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
- 11/03/2020
|
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has won the 2020 Prix Galien USA Award for Best Biotechnology Product for ONPATTRO® (patisiran). The award, which recognizes excellence in scientific innovation that improves the state of human health, was presented by the Galien Foundation during the 50th Annual Prix Galien USA Awards ceremony yesterday. “We are thrilled to receive this prestigious recognit
- 10/30/2020
|
Alnylam Named a Top Biopharma Employer by Science Magazine
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that, for the second year in a row, Science magazine has named the company a top employer in its annual survey of the biotech and pharmaceutical industry. “We are thrilled to be named a top employer by Science for the second year in a row, as we continue to build a top-tier, independent biopharmaceutical company founded on RNAi,” said John Maraganore, Ph.D., Ch
- 10/29/2020
|
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
- Over a dozen regenerative medicine drugs have been launched, generating revenues approaching $4 billion in 2019.
- 08/25/2020
|
Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease
- Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously announced $2 billion strategic financing collaboration to accelerate the advancement of RNAi therapeutics.
- 08/17/2020
|
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/15/2020
|
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $90.00 Price Target at SVB Leerink
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lifted by SVB Leerink from $89.00 to $90.00 in a research report sent to investors on Friday, BenzingaRatingsTable reports. They currently have a market perform rating on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Royal Bank of Canada started coverage on Alnylam […]
- 08/11/2020
|
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
- The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
- 08/11/2020
|
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance
- Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.
- 08/07/2020
|
Coronavirus update: U.S. case tally climbs above 4.8 million as Trump contradicts health experts to claim virus will ‘go away’
- The number of confirmed cases of the coronavirus that causes COVID-19 in the U.S. rose above 4.8 million on Thursday, a day after President Donald Trump...
- 08/06/2020
|
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
- Alnylam (ALNY) delivered earnings and revenue surprises of 12.85% and 5.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2020 and reviewed recent business highlights.
- 08/06/2020
|
Alnylam Announces Planned Transition of Barry Greene, President
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that after 17 years, Barry Greene, President, has decided to leave the Company at the end of the third quarter to pursue outside interests in the biopharmaceutical industry. Mr. Greene will remain a consultant to the Company for up to two years to ensure an orderly transition, while the search for a new Chief Commercial Officer is underway. In addition, Dr. Yvonne Greenstreet, MBChB, MBA, who currently serves as Chief Operating Officer, has been named President and Chief Operating Officer effective October 1, 2020.
- 08/06/2020
|
Alnylam Announces Planned Transition of Barry Greene, President
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that after 17 years, Barry Greene, President, has
- 08/06/2020
|
ValuEngine Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to “Buy”
- Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Monday, ValuEngine reports. A number of other equities research analysts also recently commented on ALNY. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $162.00 to $199.00 and gave the […]
- 08/05/2020
|
IPO Update: Freeline Therapeutics Proposes Terms For U.S. IPO (Pending:FRLN)
- Freeline Therapeutics Holdings plc has filed to raise $125 million in a U.S. IPO.
- 08/03/2020
|
Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1 study of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 for the treatment of nonalcoholic steatohepatitis (NASH). The Company plans to initiate a Phase 1 study in late 2020, upon obtaining MHRA approval.
- 08/03/2020
|
Dyne Therapeutics Appoints Susanna High as Chief Operating Officer
- Dyne Therapeutics today announced that it has appointed Susanna High, MBA, as its chief operating officer.
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
Biotech Bonanza - Second Half Outlook
- Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
- 07/28/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
A Top Contender in the Race for a NASH Drug Drops Out
- French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.
- 07/23/2020
|
Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2020 on Thursday, August 6, 2020, before the U.S. financial markets open.
- 07/23/2020
|
Alnylam’s Anant Murthy on making it as a US biotech in Europe -
- Alnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how a US biotech can adapt to the many unique challenges of the EU market
- 07/20/2020
|
SQZ Biotech Appoints Paul Bolno, MD to Board of Directors and Kai Wucherpfennig, MD, PhD to Scientific Advisory Board
- SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appoi
- 07/20/2020
|
Morgan Stanley Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $199.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target increased by Morgan Stanley from $162.00 to $199.00 in a research report sent to investors on Wednesday, BenzingaRatingsTable reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. BMO Capital Markets boosted their […]
- 07/19/2020
|
Fauci says U.S. needs to 'get better control' of the coronavirus to reopen without outbreaks
- Dr. Anthony Fauci said Friday that the coronavirus has hit the U.S. "very severely" and the country "needs to get better control over things" in order to reopen the economy and head toward normality.
- 07/17/2020
|
Dodge & Cox Stock Fund Q2 2020 Fact Sheet
|
Steroid's COVID-19 benefits confirmed; spotlight on immune cells
- Steroid's COVID-19 benefits confirmed; spotlight on immune cells
- 07/17/2020
|
IFM Investors Pty Ltd Sells 2,193 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- IFM Investors Pty Ltd lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 20.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,611 shares of the biopharmaceutical company’s stock after selling 2,193 shares during the period. IFM Investors Pty Ltd’s […]
- 07/16/2020
|
Alnylam (ALNY) Upgraded to Buy: Here's Why
- Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 07/14/2020
|
WSJ News Exclusive | Oat-Milk Company Oatly Draws Investment From Blackstone-Led Group Including Oprah
- Swedish oat-milk maker Oatly has sold a $200 million stake to a group led by private-equity giant Blackstone Group that includes Oprah Winfrey, Natalie Portman, former Starbucks Chief Howard Schultz and the entertainment company founded by Jay-Z.
- 07/14/2020
|
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.9% After Insider Selling
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price dropped 5.9% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $152.01 and last traded at $152.74, approximately 666,395 shares traded hands during mid-day trading. A decline of 19% from the average daily volume of 825,439 shares. The stock […]
- 07/14/2020
|
COVID-19 Impact and Recovery Analysis - Global Biodefense Market 2020-2024 | Evolving Opportunities With Alexeter Technologies LLC and Alnylam Pharmaceuticals Inc. | Technavio
- The Global Biodefense Market will grow by USD 3.22 bn during 2020-2024
- 07/14/2020
|
Coronavirus update: Global case tally edges toward 13 million, and Florida trounces one-day case record set by California last week
- The number of confirmed cases of the coronavirus illness COVID-19 worldwide edged closer to 13 million on Monday, a day after the World Health Organization...
- 07/13/2020
|
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 34%?
- Does the July share price for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reflect what it's really worth? Today, we...
- 07/13/2020
|
Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Lumasiran
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). With this decision, eligible PH1 patients in the UK, many of whom are children, can gain access to lumasiran before the drug is granted marketing authorization by the European Commission (EC).
- 07/13/2020
|
Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Lumasiran
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK’s Medicines and Healthcare Products R
- 07/13/2020
|
Did Hedge Funds Make The Right Call On Alnylam Pharmaceuticals, Inc. (ALNY) ?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/10/2020
|
Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company based in the United Arab Emirates and covering the Middle East region, announced today that they have formed a Distribution Agreement for both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.
- 07/08/2020
|
Riassunto: Alnylam Pharmaceuticals e Taiba Group formano una partnership per la commercializzazione dei composti terapeutici RNAi negli stati del Golfo
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), leader nei composti terapeutici RNAi, e taiba Middle East, importante azienda con sede negli Emirati Ara
- 07/08/2020
|
Don't 'balance lives against the economy' in unprecedented pandemic, Dr. Anthony Fauci warns
- "You don't want to balance lives against the economy," Dr. Anthony Fauci said during an interview with the JAMA Network.
- 07/02/2020
|
Stay-at-home orders helped lift several Mass. stocks in the first half of 2020 - The Boston Globe
- We are in a Work From Home World, and Wall Street knows it.
- 07/02/2020
|
Alnylam Pharma Poised to Shoot Higher
- The biopharmaceutical company shows bullish charts that signal a breakout to new all-time highs. The charts and indicators are bullish,
- 07/01/2020
|
Alnylam Pharma Poised to Shoot Higher
- The biopharmaceutical company shows bullish charts that signal a breakout to new all-time highs. The charts and indicators are bullish,
- 07/01/2020
|
From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
- Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.
- 07/01/2020
|
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
- Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb, Sanofi , Neurocrine Biosciences, Endo Pharmaceuticals and Aimmune have changed their launch plans.
- 07/01/2020
|
Quantum Workplace Honors Four Customer Companies With Its Annual Employee Voice Award
- QUANTUM WORKPLACE HONORS FOUR COMPANIES WITH ITS ANNUAL EMPLOYEE VOICE AWARD
- 07/01/2020
|
Is A Coronavirus Vaccine On The Way? Dr. Fauci Explains Timeline And Recent Spike In Cases
- “I would not be surprised if we go up to 100,000 a day if this does not turn around. And so I am very concerned” --Fauci
- 06/30/2020
|
Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new data from the open-label extension (OLE) period of the ENVISION Phase 3 study, reinforcing the long-term therapeutic benefit of givosiran in patients with acute hepatic porphyria (AHP)—an orphan disease that can be life threatening. The results were presented by study investigator Eliane Sardh, M.D., Ph.D., during a webinar hosted by Alnylam. In an interim analysis of the OLE period, givosiran, which is approved in the U.S. and EU and marketed as GIVLAARI®, demonstrated sustained efficacy and safety through 12 months of treatment, with evidence for potentially improved efficacy over time.
- 06/30/2020
|
Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new data from the open-label
- 06/30/2020
|
New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases--but Not Covid-19
- GERM offers investors exposure to established providers and ‘unsung heroes’ of biotech and life sciences Continue reading...
- 06/28/2020
|
1832 Asset Management L.P. Purchases Shares of 20,900 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- 1832 Asset Management L.P. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,900 shares of the biopharmaceutical company’s stock, valued at approximately $2,290,000. Several other institutional investors have also recently made changes […]
- 06/28/2020
|
Coronavirus update: U.S. sets another record for new cases and some states scramble to revisit their reopening plans
- The number of new confirmed cases of the coronavirus illness COVID-19 set another fresh record in the U.S. on Friday, according to data aggregated by Johns...
- 06/27/2020
|
Coronavirus update: U.S. sets record for new cases in a single day, as Texas becomes first state to reimpose restrictions
- The number of new confirmed cases of the coronavirus illness COVID-19 set a fresh record in the U.S. on Thursday of almost 40,000, according to data...
- 06/26/2020
|
Could Gilead Stock Get A Boost From Inhaled Remdesivir?
- Gilead has indicated that it would be starting clinical trials for an inhaled version of Remdesivir shortly. While the wide-spectrum anti-viral drug is currently given intravenously for severe cases of Covid-19 in the hospital, the new delivery method could enable treatment at earlier stages of...
- 06/26/2020
|
Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today | The Motley Fool
- Higher numbers of COVID-19 cases helped these biotechs, which are working on treatments and vaccines for the disease.
- 06/24/2020
|
The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
- 06/24/2020
|
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
- 06/23/2020
|
Is Alnylam a Good Biotech Stock to Buy Now? | The Motley Fool
- This biotech could earn its third new drug approval in as many years.
- 06/21/2020
|
Mackenzie Financial Corp Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Mackenzie Financial Corp increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 31.1% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,644 shares of the biopharmaceutical company’s stock after acquiring an additional 865 shares during the period. Mackenzie Financial Corp’s holdings in Alnylam Pharmaceuticals were worth […]
- 06/21/2020
|
VIR BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Alnylam Pharmaceuticals : to Host Seventh Annual 'RNAi Roundtable' Webcast Series | MarketScreener
|
GNW: Sanofi présente les données intermédiaires positives de sécurité et | Zone bourse
|
Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors | MarketScreener
|
Sanofi : présente les données intermédiaires positives de sécurité et d'efficacité à long terme de l'étude de prolongation de phase II du fitusiran chez des personnes atteintes d'hémophilie A ou B, avec ou sans inhibiteurs | Zone bourse
|
Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors
- Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B,
- 06/19/2020
|
COVID-19 Impact and Recovery Analysis - Global Biodefense Market 2020-2024 | Evolving Opportunities with Alexeter Technologies LLC and Alnylam Pharmaceuticals Inc. | Technavio
- The Global Biodefense Market will grow by $ 3.22 billion during 2020-2024
- 06/19/2020
|
Alnylam Pharmaceuticals : to Host Seventh Annual “RNAi Roundtable” Webcast Series | MarketScreener
|
Alnylam to Host Seventh Annual "RNAi Roundtable" Webcast Series
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 7th annual series of "RNAi Roundtable" webinars over the coming weeks. The series will offer a range of presentations from Alnylam scientists and program leaders, as well as clinical collaborators, who will review recent progress in many of the Company’s pipeline programs and platform. Each event will be webcast live on the Investors section of the Company’s website at www.alnylam.com/events, and a replay will be posted on the Alnylam website approximately three hours after each event.
- 06/18/2020
|
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by APG Asset Management N.V.
- APG Asset Management N.V. decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 76.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,300 shares of the biopharmaceutical company’s stock after selling 80,168 shares during the period. APG Asset Management N.V.’s holdings in […]
- 06/18/2020
|
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Decreased by M&T Bank Corp
- M&T Bank Corp lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,683 shares of the biopharmaceutical company’s stock after selling 438 shares during the period. M&T Bank Corp’s holdings […]
- 06/18/2020
|
Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 7th annual series of “R
- 06/18/2020
|
Alnylam Pharmaceuticals : to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference | MarketScreener
|
Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Securities 2020 Napa Biopharma Conference on Wednesday, June 24, 2020 at 10:30 am PT (1:30 pm ET) via webcast.
- 06/17/2020
|
Alnylam???s Share Price Rises YTD on Pipeline Developments
- Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
- 06/17/2020
|
How to buy Regeneron Pharmaceuticals shares from Australia | 17 Jun price $592.9
- Ever wondered how to buy shares in Regeneron Pharmaceuticals in Australia? We explain how and compare the best share trading platforms.
- 06/17/2020
|
Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview a
- 06/17/2020
|
Global DNA Vaccine Market Outlook to 2022 - Featuring Bharat Biotech, GlaxoSmithKline & Green Cross Among Others - ResearchAndMarkets.com
|
AlphaCrest Capital Management LLC Sells 4,598 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- AlphaCrest Capital Management LLC cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 58.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,210 shares of the biopharmaceutical company’s stock after selling 4,598 shares during the quarter. AlphaCrest Capital Management LLC’s holdings […]
- 06/14/2020
|
Coronavirus map LIVE: UK announces another 202 deaths in past 24 hours - total hits 41,481
- THE COMMON cold could help provide immunity to the deadly coronavirus for up to 17 years, a new study has found. It comes as the UK confirmed an additional 202 coronavirus deaths over the past 24 hours.
- 06/13/2020
|
Akcea: Uninteresting Slow Growth Stock With Long-Term Potential (NASDAQ:AKCA)
- AKCA is a highly uninteresting stock - perhaps just the kind we need in these times. It has two approved products and a long pipeline in rare diseases. AKCA is
- 06/12/2020
|
Regeneron starts two trials of two-antibody antiviral cocktail for Covid-19
- The company plans to test REGN-COV2 - consisting of the SARS-CoV-2-specific antibodies REGN10933 and REGN10987 - in four populations, including infected patients and uninfected people at high risk of infection.
- 06/12/2020
|
Scopus Bio preps trials of gene-silencing immuno-oncology drug -
- Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start
- 06/12/2020
|
Alnylam Pharmaceuticals : Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine | MarketScreener
|
Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that pivotal results from the ENVISION Phase 3 study of givosiran, an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP), were published online in the New England Journal of Medicine (NEJM). GIVLAARI® (givosiran) was approved by the U.S. Food and Drug Administration for the treatment of adults with AHP in November 2019, marking the first ever approval of a GalNAc-conjugate RNAi therapeutic—a landmark in the advancement of precision genetic medicines. It also received marketing authorization from the European Commission in March 2020 for the treatment of AHP in adults and adolescents aged 12 years and older. The full manuscript, titled "Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria," will appear in the June 11, 2020 issue of NEJM.
- 06/10/2020
|
Small Caps Build Steam And Biotechs Remain Well-Positioned
- Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re
- 06/10/2020
|
‘Are you immune?’ The new class system that could shape the Covid-19 world
- Experts suspect – but there is no proof – that those who have developed antibodies will have immunity. The implications could be wide-ranging
- 06/10/2020
|
Sorrento COVIDTRAP Update, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:SRNE)
- Sorrento announced a positive update on COVIDTRAP. Blueprint announced a strong trial performance. Alnylam's Lumasiran trial in phase 3 provides an encouraging
- 06/08/2020
|
Clinical Data Reaffirm That Lumasiran Will Almost Certainly Be Alnylam's Third Commercial Product (NASDAQ:ALNY)
- Full results from the pivotal ILLUMINATE-A study support the efficacy of the drug in treating PH1, with meaningful improvements in urinary oxalate levels in the
- 06/08/2020
|
Coronavirus update: Global death tally tops 400,000; Health experts urge police to stop using tear gas on anti-racism protesters
- The number of deaths from the coronavirus that causes COVID-19 rose above 400,000 on Monday, as anti-racism protests swept the U.S. and much of the rest of...
- 06/08/2020
|
Alnylam Reports Positive Phase III Results on Lumasarin
- Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.
- 06/08/2020
|
Alnylam Pharmaceuticals : BIO - Targeting 'Undruggable' Diseases | MarketScreener
|
Regeneron: Growth Plans In Immuno-Oncology (ASCO Update) (NASDAQ:REGN)
- REGN has gone from doormat to leader in short order. There have been multiple drivers of this, one of which is discussed below: immuno-oncology (IO). Behind the
- 06/08/2020
|
Alnylam's shares dip as analyst backs rival after rare disease data reveal -
- Alnylam has revealed the data that forms the basis of its filings for its latest rare disease drug contender, lumasiran, but shares dipped after an analyst suggested it could be outperformed by a contender from rival biotech Dicerna.
- 06/08/2020
|
Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick
- Alnylam Pharmaceuticals (ALNY) has announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran for the treatment of primary hyperoxaluria type 1 (PH1).PH1 is an ultra-rare orphan disease caused by excessive oxalate production, and elevated urinary oxalate levels are associated with progression to end-stage kidney disease and other systemic complications.The clinical data was presented at a virtual session of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).Lumasiran, an investigational RNAi therapeutic, achieved the primary endpoint with a 53.5% mean reduction in urinary oxalate relative to placebo (p=1.7×10-14) and showed a 65.4% mean reduction in urinary oxalate relative to baseline.All tested study secondary endpoints were met, including the proportion of patients achieving near-normalization (84%) or normalization (52%) of urinary oxalate, compared with 0% in the placebo group.Lumasiran also showed an encouraging safety and tolerability profile, with no serious or severe adverse events (AEs) and with mild injection site reactions as the most common drug-related AE.Based on these results, Alnylam has now filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The FDA has granted a Priority Review for the NDA with a December 3, 2020 action date under the Prescription Drug User Fee Act (PDUFA).In addition, the Marketing Authorisation Application (MAA) for lumasiran has received Accelerated Assessment from the European Medicines Agency (EMA).The study “represents the sixth positive Phase 3 study for an investigational RNAi therapeutic, and we believe it further highlights the transformational potential of this modality as a whole new class of medicines” said Akshay Vaishnaw, President of R&D; at Alnylam.“Overall, we think the data is solid, consistent with prior Phase I/II, and we anticipate rapid approval by the December 3rd PDUFA date” RBC Capital analyst Luca Issi told investors following the data release.However the analyst reiterated his Hold rating on the stock with a $150 price target, arguing that ALNY’s trailblazing phase 1 may actually end up providing a clearer path for rival Dicerna Pharma (DRNA)- which has a Strong Buy Street consensus.“We think DRNA is better positioned for PH given: 1) better dosing (fixed vs. weight-based dosing); 2) potential for broader label (can tackle all PH subtypes vs. only PH1); and 3) DRNA may capitalize on ALNY’s heavy lifting on building disease awareness” Issi explained. He has a buy rating on Dicerna with a $35 price target (73% upside potential).Analysts currently hold a cautiously optimistic Moderate Buy consensus on Alnylam with a $157 average price target (23% upside potential). The stock is currently trading up 11% year-to-date. (See ALNY stock analysis on TipRanks)Related News: AbbVie’s Rinvoq Beats Bristol-Myers’ Orencia In New Rheumatoid Arthritis Data Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed More recent articles from Smarter Analyst: * Boeing (BA) Stock Probably Rallied Too Far, Too Fast * Latam Airlines' Shares Could Be Heading Further South; Top Analyst Says 'Sell' * Starbucks’ (SBUX) Road to Recovery Will Take Longer Than Anticipated, Says Analyst * TripAdvisor: Post Pandemic, Many Challenges Await
- 06/08/2020
|
Alnylam Say Lumasiran Met Primary Efficacy Endpoint of 24-hour Urinary Oxalate Reduction from Month 3 to 6 Relative to Placebo, All Tested Secondary Endpoints
|
Alnylam Pharmaceuticals : Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1 | MarketScreener
|
Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The clinical data were presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held as a virtual event on June 6-9.
- 06/07/2020
|
Coronavirus (Covid-19) vaccine latest update: Brazil approves Oxford corona vaccine trials; Moderna to start final phase in July
- Coronavirus (Covid-19) Vaccine Latest Update: US has selected five companies as the most likely candidates to produce a vaccine; Moderna is looking to start final phase of trials as early as July.
- 06/07/2020
|
Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A st
- 06/07/2020
|
New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 H
- 06/06/2020
|
Dr. Anthony Fauci says large protests taking place across the country are 'a perfect set-up' for spreading COVID-19
- Dr. Anthony Fauci, the head of the National Institute for Allergy and Infectious Diseases, said in a Friday interview on D.C.-based radio station WTOP he is concerned that the widespread protests taking place across the country could raise the risk of new COVID-19 outbreaks as the country seeks to re-open.
- 06/05/2020
|
‘We don’t inevitably have to have a second wave,’ says Anthony Fauci, top U.S. infectious-diseases doctor
- ‘We will have coronavirus in the fall: I am convinced of that,’ Fauci said two months ago.
- 06/05/2020
|
Dr. Anthony Fauci says Americans who don't wear masks may 'propagate the spread of infection'
- White House health advisor Dr. Anthony Fauci made his comments Friday on CNBC.
- 06/05/2020
|
Why Is Alnylam (ALNY) Down 6.8% Since Last Earnings Report?
- Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 06/05/2020
|
Mattis' rebuke of Trump forces Republicans to choose between revered Marine and president
- WASHINGTON - Former defense secretary Jim Mattis' strong rebuke of President Donald Trump forced Republicans to choose sides between a revered retired Marine Corps general and a leader with a near-stranglehold on the party and the voters critical to their election.
Mattis moved one senior Senate Republican to finally declare she had to speak out against Trump's handling of the racial injustice protests, and more broadly about his overall moral leadership, while signaling she may not support him in November.
"When I saw General Mattis' comments yesterday, I felt like perhaps we're getting to the point where we can be more honest with the concerns that we might hold internally, and have the courage of our own convictions to speak up," Sen. Lisa Murkowski, R-Alaska, chair of the Energy and Natural Resources Committee, said Thursday.
Murkowski, the 10th-longest-serving active GOP senator, told reporters that she agreed with Mattis' broadside that Trump tries to deliberately divide Americans and the nation was "witnessing without mature leadership."
"I thought General Mattis' words were true and honest and necessary and overdue," Murkowski told reporters at the Capitol.
Her comments stood out among Republicans, who for the most part either remained silent in the wake of Mattis's criticism, accused the media of trying to stir controversy or offered supportive words for Trump.
Yet it served as a stunning denunciation from within a party whose leaders on Capitol Hill have either marched in lockstep with Trump or ducked any of his controversial moves, to the point that Sen. Mitt Romney, R-Utah, was the only Republican to vote to convict Trump at his impeachment trial earlier this year.
Romney initially avoided addressing the matter, but after Murkowski spoke out, he joined in...
- 06/05/2020
|
Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Getting Bullish
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 06/04/2020
|
What you need to know today about the virus outbreak
- The United Nations is among organizations urging those companies developing coronavirus vaccines to create one that would be free to everyone once it's developed
- 06/04/2020
|
Regeneron: Favorable Performance Of Current Product Portfolio, Impressive Pipeline Bode Well For Growth Over The Next Decade (NASDAQ:REGN)
- Regeneron has both added to its current growth drivers and developed an impressive pipeline that should fuel performance throughout the decade. Eylea will benef
- 06/04/2020
|
Gilead Drug Remdesivir’s Use Against Coronavirus Could Become Obsolete, Analyst Says
- In study results published last week, the Gilead drug seemed to get patients off a ventilator sooner than existing treatments. But an analyst notes the anomaly that patients on the drug for 5 days did better than those on it for 10 days.
- 06/02/2020
|
Alnylam Pharmaceuticals : Announces Recipients of Second Annual Advocacy for Impact Grants Program | MarketScreener
|
Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that seven patient advocacy groups will receive supportive funding as part of the company’s second annual Advocacy for Impact grants program. The global competitive grants program aims to inspire patient advocacy groups to develop solutions that address critical unmet needs among the hereditary transthyretin-mediated (hATTR) amyloidosis, acute hepatic porphyria (AHP) and primary hyperoxaluria type 1 (PH1) rare disease communities.
- 06/02/2020
|
Regeneron Pharmaceuticals, Inc. (REGN) Regeneron Oncology Investor Event, ASCO 2020 Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Regeneron Oncology Investor Event, ASCO 2020 Conference Call June 01, 2020 04:30 PM ET Company Participants Justin
- 06/02/2020
|
Fauci says his contact with Trump has 'dramatically decreased'
- Comments likely to raise fears he is being squeezed out of White House as coronavirus continues to ravage US
- 06/02/2020
|
Coronavirus live news: Dr Fauci says he hasn't spoken to Trump in two weeks as Pakistanis told to 'live with virus'
- UK’s 14-day quarantine rules criticised as ‘ridiculous’; Global deaths near 375,000; Spain reports no new deaths for the first time since March. Follow the latest updates
- 06/02/2020
|
Xconomy: Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact
- Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases,
- 06/01/2020
|
Anthony Fauci on Covid-19 reopenings, vaccines, and moving at 'warp speed'
|
Alnylam Pharmaceuticals : to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress | MarketScreener
|
Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a webcast conference call on Sunday, June 7, 2020 at 8:30 am ET. Lumasiran is an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The clinical data will be presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held June 6-9 as a virtual event.
- 06/01/2020
|
Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss full results from th
- 06/01/2020
|
Why virus stocks are driving market volatility
- The market’s erratic response to lukewarm medical research for COVID-19 treatment and vaccine candidates isn’t expected to slow down as investors pin their...
- 05/30/2020
|
Alnylam's NDA Accepted, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:ALNY)
- Alnylam's Lumasiran NDA has been accepted. Argenx reports positive data from Efgartigimod trial. Co-Diagnostics discusses its coronavirus test kit.
- 05/29/2020
|
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen
- Johnson & Johnson today announced that its Janssen Pharmaceutical Companies received a positive opinion from the Committee for Medicinal Products
- 05/29/2020
|
UBS Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $122
|
Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA
- Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.
- 05/27/2020
|
Alnylam Pharmaceuticals : to Webcast Presentations at Upcoming June Investor Conferences | MarketScreener
|
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
- 05/26/2020
|
New Coronavirus Vaccine Candidate: Novavax Starting Clinical Trials Of NVX-COV2373 To Fight Pandemic
- The first phase of the trial will enroll 130 healthy individuals ages 18 to 59 and take place in Australia while phase 2 will be conducted in multiple countries and widen the age range.
- 05/26/2020
|
Pfizer Is Charging Ahead With A Coronavirus Vaccine — Is PFE Stock A Buy?
- Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?
- 05/26/2020
|
New Coronavirus Vaccine To Send Virus' Spike Protein To Activate Body's Immune Response
- Novavax is now beginning its clinical trials.
- 05/26/2020
|
Alnylam Announces FDA Has Granted Priority Review Of Lumasiran New Drug Application For Primary Hyperoxaluria Type 1
|
Alnylam Pharmaceuticals : Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1 | MarketScreener
|
Edited Transcript of ALNY earnings conference call or presentation 6-May-20 12:30pm GMT
- Q1 2020 Alnylam Pharmaceuticals Inc Earnings Call
- 05/26/2020
|
Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The FDA also granted Priority Review for the NDA, a designation for medicines that have the potential to provide significant improvements in the treatment, prevention or diagnosis of a serious disease, with the goal of FDA taking action within six months compared to 10 months under standard review.
- 05/26/2020
|
Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA)
- 05/26/2020
|
Alnylam Pharmaceuticals : Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO at the European Academy of Neurology Virtual Congress 2020 | MarketScreener
|
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
- Is (ALNY) Outperforming Other Medical Stocks This Year?
- 05/25/2020
|
HCQ: what we know so far
- India has extended guidelines for hydrochloroquine use, a study has raised fresh questions about its efficacy against Covid, and Trump continues to push for it. A look at both sides of the continuing debate.
- 05/25/2020
|
National security adviser says US considering banning travel from Brazil over coronavirus outbreak
- National security adviser Robert O'Brien said the United States will make a decision on whether to ban travel from Brazil on Sunday.
- 05/24/2020
|
Four days of work, followed by 10 days of lockdown could help prevent another wave of infections. Here's how the idea compares to other reopening strategies.
- Researchers have a plan to mitigate the risk of a second wave of coronavirus infections – a scenario many experts think is likely. For some, it’s an alternating cycle of four days at the office, then 10 days under lockdown. For others, it’s a switch-off between 50 days under stay-at-home orders and 30 days of relative freedom.
- 05/24/2020
|
Alnylam's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:ALNY)
- Alnylam announces positive ONPATTRO trial data. Geron to start phase 3 trial in Myelofibrosis. Atara reports successful early stage data.
- 05/24/2020
|
3 Stocks To Watch In The Coming Week: Salesforce.com, Costco, Dell
- Stocks Analysis by Investing.com (Haris Anwar/Investing.com) covering: S&P 500, Dow Jones Industrial Average, Microsoft Corporation, Dell Technologies Inc. Read Investing.com (Haris Anwar/Investing.com)'s latest article on Investing.com
- 05/24/2020
|
Here's what happened to the stock market on Friday
- Stocks were mostly flat on Friday as Wall Street wrapped up a solid week of gains.
- 05/22/2020
|
Fauci: US 'can't stay locked down'
- Dr. Anthony Fauci said he is “totally in favor” of various states reopening if done correctly.
- 05/22/2020
|
Unemployment Exceeds 20% in These 3 States
- Here’s what you need to know about the coronavirus outbreak to navigate the markets today.
- 05/22/2020
|
Alnylam Pharmaceuticals : Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020 | MarketScreener
|
Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from the Global Open-Label Extension (OLE) study of ONPATTRO® (patisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults, at the European Academy of Neurology (EAN) Virtual Congress. In addition, interim results were presented from a Phase 3b trial evaluating treatment with patisiran in patients with hATTR amyloidosis with disease progression after receiving an orthotopic liver transplant (post-OLT).
- 05/22/2020
|
Stocks Eye Weekly Gains Despite Mounting China Tensions - Schaeffer's Investment Research
- The stock market is lower midday as U.S.-China tensions weigh, though all three indexes eye weekly gains
- 05/22/2020
|
Fauci Calls Moderna's Coronavirus Vaccine Candidate 'Quite Promising'
- Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, is “cautiously optimistic” about Moderna Inc's (NASDAQ: MRNA) ...
- 05/22/2020
|
Is Alnylam Pharmaceuticals a Buy?
- Alnylam Pharmaceuticals (NASDAQ: ALNY) has been a phenomenal biotech stock. The company had its initial public offering in 2004. Shares are now 22 times more valuable than they were 16 years ago. That's an incredible stock performance.
- 05/21/2020
|
Top Pharmaceutical Company Visionaries to Keynote Veeva Summit Online
- Alnylam and Pfizer to discuss how innovative oncology and specialty medicines are transforming commercial models and helping improve patients' lives
- 05/21/2020
|
Ionis: Uncertain Revenues Hamper Valuation. Share Price Can Gain On Spinraza, Pipeline (NASDAQ:IONS)
- Ionis share price is down 21% year on year, falling from $66 to $52. In March '19, the stock had traded at all-time highs of $85. The company earns revenues fro
- 05/20/2020
|
Trump administration paying huge premium for mask-cleaning machines. Which don't do the job.
- The president pressured the FDA to waive rules for mask-cleaning machines that ballooned to 10 times the original cost. But the process may damage the masks, NBC news reports.
- 05/20/2020
|
Can hydroxychloroquine prevent a COVID-19 infection? That’s Trump’s hope, it appears — and it is being looked into by researchers
- President Donald Trump’s unprompted admission that he’s been taking hydroxychloroquine to prevent a COVID-19 infection fits into a broader trend of medical...
- 05/19/2020
|
Don't get excited about Moderna's coronavirus vaccine just yet
- Full results for the other 37 subjects in Moderna's Phase 1 trial haven't been reported. Nor have Moderna's results been subjected to peer review.
- 05/19/2020
|
Moderna coronavirus vaccine trial shows promising early results
- Eaight healthy volunteers, ages 18 to 55, made antibodies that were then tested in infected cells in the lab and were able to stop the virus from replicating — the key requirement for an effective vaccine
- 05/18/2020
|
Moderna’s stock soars on ‘compelling’ early data for its coronavirus vaccine candidate
- The people who were given Moderna Inc.’s (TICKER:MRNA) coronavirus vaccine candidate in a Phase 1 clinical trial developed neutralizing antibodies, a...
- 05/18/2020
|
Pfizer Just Began A Coronavirus Vaccine Test — Is PFE Stock A Buy?
- Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?
- 05/18/2020
|
Explained: How human challenge works
- Coronavirus (Covid-19) Vaccine: In the hunt for a virus, over 20,000 people worldwide have volunteered to infect themselves with coronavirus. How frequent are such trials, what is the objective, and what precautions are taken?
- 05/18/2020
|
Hedge Fund Duquesne 13F Shows Increased Stakes In Facebook, Alibaba, Netflix, Amazon, Google, Alnylman
|
Editorial: Is the worst of the coronavirus still to come?
- Rick Bright was the latest in a succession of experts to sound the alarm about a resurgence that could do more damage than the first wave of the pandemic in the absence of a more cautious and coordinated approach.
- 05/15/2020
|
Kemnay Advisory Services Inc. Buys Apple Inc, Netflix Inc, Alnylam Pharmaceuticals Inc, Sells ...
|
